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Objective: This study investigated the incidence and clinical significance of homeodomain-
interacting protein kinase 1 expression in breast cancer patients.
Methods: We investigated immunohistochemical homeodomain-interacting protein kinase 1
expression from tissue microarrays of 1032 patients. The association of homeodomain-inter-
acting protein kinase 1 expression pattern, clinicopathologic factors and survival outcome was
evaluated. Tumors with 10% stained cells were considered positive for homeodomain-inter-
acting protein kinase 1.
Results: Non-cancerous breast tissue, pTis and pT1mic lesions did not show homeodomain-
interacting protein kinase 1 expression at any sites. Of the 859 invasive tumors, 124 (14.4%)
showed homeodomain-interacting protein kinase 1 expression with three different expression
patterns: cytoplasmic (2.4%), nuclear (6.3%), and both cytoplasmic and nuclear (5.7%).
Cytoplasmic homeodomain-interacting protein kinase 1-positive tumors showed distinctive
features such as fewer nodal metastases, but were frequently Grade III, estrogen receptor-
negative, progesterone receptor-negative, HER2-positive, highly proliferative and molecular
apocrine tumors. No significant difference in clinicopathologic features was identified between
negative and nuclear homeodomain-interacting protein kinase 1-positive tumors. Both cyto-
plasmic and nuclear HIPK1-positive tumors represent frequent small size, node negativity
and moderately differentiated features. Survival was not significantly different by homeodo-
main-interacting protein kinase 1 expression patterns.
Conclusions: Homeodomain-interacting protein kinase 1 expression was identified only in
invasive breast cancer cells with three different patterns: cytoplasmic, nuclear, and both cyto-
plasmic and nuclear. Although the mechanism is not certain, the subcellular localization of
HIPK1 expression is associated with tumor histopathologic characteristics and different
functions.
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INTRODUCTION
The homeodomain-interacting protein kinases (HIPKs) are
members of a small family of nuclear serine/threonine
kinases that includes HIPK1, HIPK2 and HIPK3 (1). HIPK1
is primarily localized in the nucleus where it is sumoylated
(2,3). HIPKs may recognize multiple cellular inputs and
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regulate cell proliferation and apoptosis by regulating the ac-
tivity of interacting proteins and subsequently the transcrip-
tion of various target genes (4). HIPKs might be involved in
the integration of various extracellular stimuli and the medi-
ation of appropriate cellular responses during embryogenesis.
HIPK2 is relatively well studied and is involved in
DNA-damage response, signaling to p53 by phosphorylating
Ser-46, which triggers an apoptotic response through the
upregulation of pro-apoptotic p53 target genes (5–7).
Nodale et al. (8) reported that HIPK2 overexpression can
contribute to the inhibition of breast cancer cell migration
and invasion by vimentin downregulation.
On the contrary, HIPK1 is less well studied than HIPK2
and its function appears to be complex. The HIPK1 gene is
highly expressed from human chromosome band 1p13, a site
frequently altered in cancers. Mouse HIPK1 has been sug-
gested to act as a transcriptional co-repressor interacting with
the homeoproteins NKx-1,2 and NK-1 (2). Kondo et al. (9)
isolated the p53-binding kinase HIPK1 and showed the upre-
gulation of HIPK1 in many tumor cell lines. They also
showed that carcinogen-treated HIPK12/2 mice developed
fewer and smaller skin tumors than HIPK1þ/þ mice and
that the loss of HIPK1 had a protective effect on malignant
progression by demonstrating that HIPK12/2 transformed
mouse embryonic ﬁbroblast colonies grew more slowly than
equivalent HIPK1þ/þ cells (9). Lee et al. (10) also reported
that the cell growth rate of HIPK1 knockdown cell lines was
markedly reduced compared with parental and control A549
cells and the tumorigenic activity of A549 lung cancer cells
was reversed on suppression of HIPK1 expression in a soft
agar assay and xenograft nude mice model. Taken together,
these data suggest antiapoptotic and oncogenic function for
HIPK1. However, HIPK1 is desumoylated in response to
tumor necrosis factor (TNF)-a, and desumoylated HIPK1 is
exported to cytoplasm where it binds to the AIP1-ASK1 sig-
naling complex leading to the activation of ASK1-JNK/P38
signaling and endothelial cell apoptosis (11). Therefore,
HIPK1 may play contradictory roles of antiapoptotic and
apoptotic by desumoylation and relocalization.
Since sumoylation is associated with the modiﬁcation of
protein function and subcellular localization, desumoylation
and relocalization of HIPK1 may affect the tumor growth or
differentiation. Few studies have explored HIPK1, and its
function has not been investigated or identiﬁed. Therefore,
we designed this study to investigate the incidence of HIPK1
expression, patterns of expression and its association with
clinicopathologic parameters in breast cancer.
PATIENTS AND METHODS
PATIENT SELECTION
Tumor samples were collected between November 1999 and
August 2005, and formalin-ﬁxed and parafﬁn-embedded.
Archival hematoxylin and eosin (H&E)-stained slides for
each case were reviewed by breast pathologists.
Immunohistochemistry (IHC) was interpreted in a blind
fashion, without information regarding clinical parameters or
outcomes. Among the initial study population of 1200 cases,
157 cases (13.1%) with unreadable or duplicated HIPK1 ex-
pression and 11 cases (0.9%) with metastatic or recurrent
disease at diagnosis were excluded. A total of 1032 cases
were enrolled for analyses. Of these, 106 cases (10.3%) with
invasive carcinoma that did not have invasive foci upon the
review of archival H&E-stained slides were included and
represented only extensive intraductal components (EIC).
This study was approved by the Institutional Review Board
of Severance Hospital, Yonsei University Health System,
Seoul, Korea (4-2011-0354).
Patient characteristics, recurrence patterns and survival
were regularly updated with regular follow-up information
obtained from the breast cancer registry of the Yonsei
University Severance Hospital. Patients received standard
surgical procedures, either total mastectomy or breast-
conservation surgery and sentinel lymph node biopsy or axil-
lary lymph node dissection. After surgery, local radiotherapy
or adjuvant treatments were decided by the results of risk
evaluation. Clinical follow-up included history-taking, phys-
ical examinations, laboratory tests and radiologic imaging
every 6–12 months for detection of relapse. Tumor stage
was based on the Sixth American Joint Committee on
Cancer criteria (12). Histological grade was assessed by the
modiﬁed Bloom–Richardson classiﬁcation (13). Locoregional
recurrence was deﬁned as tumor recurrence in the ipsilateral
breast, chest wall and regional lymph node. Any recurrence at
a distant site including contralateral axillary or supraclavicular
lymph nodes was considered as a distant metastasis.
Disease-free survival (DFS) was measured from the date of
the ﬁrst curative surgery to the date of the ﬁrst locoregional or
systemic recurrence, or death before any type of relapse.
Overall survival (OS) was calculated from the date of the ﬁrst
surgery to the date of the last follow-up or death from any
cause.
TISSUE MICROARRAY AND IHC
Formalin-ﬁxed, parafﬁn-embedded tissue blocks were
arrayed using a tissue-arraying instrument (AccuMax Array,
Petagen, Inc., Seoul, Korea). On each H&E slide of tumor
blocks, invasive and/or intraductal components were selected
and corresponding areas were marked on the surface of
tumor blocks. The designated zone of each donor block was
punched with a tissue cylinder and a core sample of 3 mm in
diameter was transferred to a 6  5 recipient block in a grid
pattern. Each core was assigned a unique tissue microarray
(TMA) location number linked to a database containing clin-
icopathologic parameters.
TMA blocks were subjected to IHC. Brieﬂy, 5 mm sec-
tions were obtained, deparafﬁnized and rehydrated. After
treatment with 3% hydrogen peroxide solution for 10 min to
block endogenous peroxidase, the sections were pretreated in




















10 mM citrate buffer for antigen retrieval in a microwave
oven for 20 min. After incubation with primary antibodies
against HIPK1 (monoclonal, 1:30; catalog No. ab58136,
Abcam, Cambridge, MA), estrogen receptor (ER) (SP1,
1:100; Thermo Scientiﬁc, Fremont, CA), progesterone recep-
tor (PR) (PgR 636, 1:50; DAKO, Glostrup, Denmark),
human epidermal growth factor receptor 2 (HER2) (poly-
clonal, 1:1,500; DAKO), Ki-67 (MIB-1, 1:100; DAKO), or
androgen receptor (AR) (AR 441, 1:100; Thermo
Scientiﬁc), immunodetection was performed with biotiny-
lated antimouse/rabbit immunoglobulin, followed by
peroxidase-labeled streptavidin using a labeled streptavidin
biotin kit with 3,30-diaminobenzidine chromogen as a sub-
strate. Slides were counterstained with hematoxylin.
Appropriate control tissues including skeletal muscle for
HIPK1 were used as positive controls and non-cancerous
breast tissue samples were also included in the TMA
blocks.
Tumors with 10% or more cells expressing HIPK1 in the
cytoplasm, nucleus, or at both sites were considered to be
positive. Therefore, HIPK1 expression was categorized as
either negative or positive for the cytoplasm, nucleus, or
both. Tumors with 1% nuclear-stained cells were consid-
ered positive for ER and PR according to the American
Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) guidelines (14). HER2 IHC and
ﬂuorescence in situ hybridization (FISH) were performed in
all cases. HER2 IHC was interpreted as 0, 1þ, 2þ or 3þ
and FISH was deﬁned as positive in cases with an absolute
HER2 gene copy number .6 or HER2 gene/chromosome
17 copy number ratio .2.2 according to the ASCO/CAP
guidelines (15). HER2 was considered to be positive in cases
with IHC 3þ score or positive FISH regardless of IHC
results. Tumors with 10% or more positively nuclear-stained
cells were considered positive for AR (16). Based on IHC or
FISH results of ER, PR, HER2 and Ki-67, molecular
subtype was categorized as follows: luminal A (ERþ and/or
PRþ, HER22 and Ki-67 ,14%); luminal B (ERþ and/or
PRþ, HER22 and Ki-67 14% or ERþ and/or PRþ and
HER2þ irrespective of Ki-67 expression); HER2-enriched
(ER2, PR2 and HER2þ); and triple negative breast cancer
(TNBC) (ER2, PR2 and HER22). The molecular apocrine
subtype was immunohistochemically deﬁned as ER-negative
and AR-positive tumors (17).
STATISTICAL ANALYSIS
Differences between the groups were evaluated by a chi-
square test. Fisher’s exact test was used when appropriate.
Survival curves were plotted using the Kaplan-Meier method
and group differences in survival time were investigated by a
log-rank test. All statistical tests were two-sided and P,
0.05 was considered statistically signiﬁcant. SPSS for
Windows version 18.0 (SPSS, Inc., Chicago, IL) was used
for all statistical analysis.
RESULTS
WHOLE-POPULATION HIPK1 EXPRESSION
The study population of 1032 tumors was composed of 38 in
situ carcinomas (pTis, 3.7%), 29 microinvasive cancer
(pT1mic, 2.8%), 106 EIC of invasive tumors (10.3%), 385
pathologic tumor stage 1 (pT1, 37.3%), 448 pT2 (43.4%)
and 26 pT3-4 (2.5%) carcinomas. Of a total 1032 cases, 907
(87.9%) tumors were negative for HIPK1 expression, 21
(2.0%) were cytoplasmic, 55 (5.3%) were nuclear and 49
(4.7%) showed both (Fig. 1A–D.). Non-cancerous breast
tissue did not show HIPK1 expression at any sites (Fig. 1E).
The frequency of HIPK1 expression according to tumor
stage is in Table 1. All core samples from the pT1mic and
EIC represented intraductal tumor cells by review of archival
H&E slides. No lesions with pTis and pT1mic showed
HIPK1 expression at any sites. Of 106 EIC lesions, only one
(0.9%) showed HIPK1 expression. The other 105 samples
(99.1%) did not show HIPK1 expression. Among invasive
cancers, expression patterns of HIPK1 were not signiﬁcantly
different between pT1 and pT2-4 carcinomas (chi-square
test, P ¼ 0.127). Among 859 invasive cancers, 124 cases
(14.4%) showed HIPK1 expression in the cytoplasm (21
cases, 2.4%), nucleus (54 cases, 6.3%) or both (49 cases,
5.7%) (Table 1).
CLINICOPATHOLOGIC PARAMETERS OF INVASIVE CANCER PATIENTS
Clinicopathologic characteristics and survival outcomes were
investigated for 859 patients with invasive cancer. The mean
with standard deviation (SD) of age at diagnosis was 49.0+
10.5 years (range, 20–87). Among the 859 patients, 385
(44.8%) patients had pT1 carcinoma and 435 (50.6%) pre-
sented axillary node-negative tumors. Histologic grade was I
in 157 (18.3%), II in 463 (53.9%) and III in 239 (27.8%)
cases. Expression was positive for ER in 618 (71.9%), for
PR in 536 (62.4%) and AR in 472 cases (54.9%). HER2
overexpression or ampliﬁcation was identiﬁed in 211 tumors
(24.6%). Of the 858 patients who were available for Ki-67
proliferative index, 477 (55.6%) showed Ki-67 ,10%, 229
(26.7) had a Ki-67 index of 10–19% and 152 (17.7%) had a
Ki-67 index of 20% or higher. Breast-conservation surgery
was performed in 246 (28.6%) patients and local radiother-
apy was administered to 411 (47.8%). Adjuvant chemother-
apy and endocrine therapy was administered to 745 (86.7%)
and 565 (65.8) patients, respectively.
CHARACTERISTICS AND SURVIVAL ACCORDING TO HIPK1
EXPRESSION AMONG INVASIVE CANCERS
Of the 859 invasive cancers, HIPK1 expression was negative
in 735 cancers (85.6%), cytoplasmic in 21 (2.4%), nuclear in
54 (6.3%), and both cytoplasmic and nuclear in 49 (5.7%)
tumors. Positive HIPK1 expression was seen in 124 (14.4%)




















patients, in three patterns. Patient characteristics by HIPK1
expression are in Table 2.
No signiﬁcant difference was seen in clinicopathologic
features between negative and nuclear HIPK1-expressing
tumors (chi-square tests between negative and nuclear
HIPK1 subgroups, P . 0.05 for each clinicopathologic char-
acteristic). The most prominent features were for cytoplasmic
HIPK1-expressing tumors. Compared with tumors with nega-
tive HIPK1 expression, those with cytoplasmic HIPK1 ex-
pression showed fewer regional node metastases, but were
frequently poorly differentiated Grade III, ER-negative,
PR-negative, HER2-positive and highly proliferative
Ki-67-positive cancers. They were also associated with
HER-enriched subtype and molecular apocrine tumors.
Tumors with HIPK1 expression in both the cytoplasm and
nucleus showed the characteristics between nuclear and cyto-
plasmic expression. They were frequently small, node-
negative cancers, but were associated with moderately differ-
entiated tumor. A moderate frequency of HER2 overexpres-
sion and Ki-67 positivity were also noted. For molecular
subtype deﬁned by IHC, tumors expressing cytoplasmic
HIPK1 were associated with HER2-enriched subtype.
Tumors expressing both cytoplasmic and nuclear HIPK1
were associated with luminal B subtype, but the proportion
of TNBC did not differ by HIPK1 expression patterns.
The median follow-up duration was 86.3 months (range,
5–137) for all patients. The sample sizes of the expression
categories were too small to determine signiﬁcant survival
difference according to HIPK1 expression patterns. DFS and
OS according to HIPK1 expression are shown in Fig. 2.
Five-year DFS rates for patients with tumors that were
HIPK1 negative, cytoplasmic, nuclear or both were 83.2,
85.7, 83.3 and 83.7%, respectively; 5-year OS rates were
89.9, 95.2, 83.3 and 91.8%. Survival outcomes were not
Figure 1. Expression pattern of HIPK1 in cancerous and non-cancerous breast tissues. Microscopic ﬁndings of negative (A), cytoplasmic (B), nuclear (C) and
both cytoplasmic and nuclear (D) HIPK1-expressing tumors and non-cancerous breast tissue (E) (200).
Table 1. HIPK1 expression according to pathologic tumor stage (pT)
pTis (n ¼ 38, %) pT1mic (n ¼ 29, %) EIC (n ¼ 106, %) pT1 (n ¼ 385, %) pT2–4 (n ¼ 474, %)
HIPK1
Negative 38 (100) 29 (100) 105 (99.1) 323 (83.9) 412 (86.9)
Cytoplasmic 0 (0.0) 0 (0.0) 0 (0.0) 9 (2.3) 12 (2.5)
Nuclear 0 (0.0) 0 (0.0) 1 (0.9) 23 (6.0) 31 (6.5)
Both 0 (0.0) 0 (0.0) 0 (0.0) 30 (7.8) 19 (4.0)
Is, in situ carcinoma; mic, microinvasive carcinoma; EIC, extensive intraductal components associated with invasive cancer.




















Table 2. Clinicopathologic characteristics according to HIPK1 expression in 859 patients with invasive carcinoma
HIPK1 expression patterns P value
Negative (n ¼ 735, %) Cytoplasmic (n ¼ 21, %) Nuclear (n ¼ 54, %) Both cytoplasmic and
nuclear (n ¼ 49, %)
Age at diagnosis (years)
35 54 (7.3) 0 (0.0) 5 (9.3) 5 (10.2) 0.484*
.35 681 (92.7) 21 (100) 49 (90.7) 44 (89.8)
Age at diagnosis (years)
50 465 (63.3) 10 (47.6) 41 (75.9) 29 (59.2) 0.098
.50 270 (36.7) 11 (52.4) 13 (24.1) 20 (40.8)
Pathologic tumor stage
T1 323 (43.9) 9 (42.9) 23 (42.6) 30 (61.2) 0.085*
T2 392 (53.3) 12 (57.1) 27 (50.0) 17 (34.7)
T3-4 20 (2.7) 0 (0.0) 4 (7.4) 2 (4.1)
Pathologic node stage
N0 359 (48.8) 16 (76.2) 25 (46.3) 35 (71.4) 0.005*
N1 226 (30.7) 3 (14.3) 14 (25.9) 3 (6.1)
N2 93 (12.7) 2 (9.5) 9 (16.7) 5 (10.2)
N3 57 (7.8) 0 (0.0) 6 (11.1) 6 (12.2)
Histologic grade
I 139 (18.9) 2 (9.5) 12 (22.2) 4 (8.2) ,0.001
II 400 (54.4) 4 (19.0) 25 (46.3) 34 (69.4)
III 196 (26.7) 15 (71.4) 17 (31.5) 11 (22.4)
Estrogen receptor
Negative 205 (27.9) 10 (47.6) 15 (27.8) 11 (22.4) 0.190
Positive 530 (72.1) 11 (52.4) 39 (72.2) 38 (77.6)
Progesterone receptor
Negative 265 (36.1) 12 (57.1) 22 (40.7) 24 (49.0) 0.069
Positive 470 (63.9) 9 (42.9) 32 (59.3) 25 (51.0)
HER2
Negative 568 (77.3) 10 (47.6) 38 (70.4) 32 (65.3) 0.004
Positive 167 (22.7) 11 (52.4) 16 (29.6) 17 (34.7)
Androgen receptor
Negative 338 (46.0) 10 (47.6) 21 (38.9) 18 (36.7) 0.473
Positive 397 (54.0) 11 (52.4) 33 (62.1) 31 (63.3)
Ki-67 (%, n ¼ 858)
,10 415 (56.5) 3 (14.3) 35 (64.8) 24 (49.0) 0.001
10 319 (43.5) 18 (85.7) 19 (35.2) 25 (51.0)
Subtype (n ¼ 858)
Luminal A 398 (54.2) 4 (19.0) 28 (51.9) 22 (44.9) 0.015*
Luminal B 152 (20.7) 7 (33.3) 11 (20.4) 16 (32.7)
HER2-enriched 58 (7.9) 6 (28.6) 5 (9.3) 4 (8.2)
TNBC 126 (17.2) 4 (19.0) 10 (18.5) 7 (14.3)
Molecular apocrine tumor
Continued




















signiﬁcantly different according to the HIPK1 expression
status (DFS, P ¼ 0.861; OS, P ¼ 0.690). DFS was not sig-
niﬁcantly different when stratiﬁed by the lymph node, ER,
HER2 or Ki-67 status or according to the HIPK1 status
when stratiﬁed by TNM stage or molecular subtype, though
cytoplasmic HIPK1-postive tumors showed a relatively
better survival trend in node-positive subgroup,
HER2-postive and ER-negative subgroups (data not shown).
DFS and OS according to HIPK1 expression for 59 molecu-
lar apocrine subtype tumors are shown in Fig. 3. No recur-
rence or death was seen in ﬁve patients with molecular
apocrine tumors expressing cytoplasmic HIPK1, although
this was not statistically signiﬁcant.
DISCUSSION
In our study, HIPK1 expression was detected in only 1 of
the 173 intraductal tumor samples (0.58%) but increased ex-
pression of HIPK1 was detected in 124 of 859 (14.4%)
invasive breast cancer tissues. We observed three HIPK1 ex-
pression patterns: cytoplasmic (2.4%), nuclear (6.3%) and
both cytoplasmic and nuclear (5.7%) expression. HIPK1 is
expressed mainly in invasive breast cancer cells but not in
intraductal cancer cells, which suggests that HIPK1 expres-
sion might not be an early event in cancer development.
HIPK1 is sumoylated and primarily localized in the nucleus
with a novel dot-like subnuclear distribution (2,3), they are
also found in the cytoplasm (3,18). Since sumoylation is a
post-translational modiﬁcation by a small ubiquitin-like
modiﬁer and can modify the protein function and desumoy-
lation is associated with cytoplasmic translocation of HIPK1.
Therefore, HIPK1 may play different roles depending on the
sites of expression such as localization in the nucleus, in the
cytoplasm or in both sites.
As shown in Table 2, signiﬁcantly different clinicopatho-
logic features were noted by HIPK1 expression patterns.
Signiﬁcant differences were seen in cytoplasmic
HIPK1-expressing tumors, which showed fewer regional
node metastases but frequently had poorly differentiated
Table 2. Continued
HIPK1 expression patterns P value
Negative (n ¼ 735, %) Cytoplasmic (n ¼ 21, %) Nuclear (n ¼ 54, %) Both cytoplasmic and
nuclear (n ¼ 49, %)
Apocrine subtype 46 (6.3) 5 (23.8) 4 (7.4) 4 (8.2) 0.035*
Other types 689 (93.7) 16 (76.2) 50 (92.6) 45 (91.8)
HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.
*Fisher’s exact test.
Figure 2. Disease-free (A) and overall (B) survival according to HIPK1 status. The solid line (a) represents negative HIPK1; dotted line (b), cytoplasmic
HIPK1; dashed line (c), nuclear HIPK1 and dash-dotted line (d), both cytoplasmic and nuclear HIPK1 expression.




















Grade III, ER-negative, PR-negative, HER2-positive and
highly proliferative Ki-67-positive features. They were also
associated with HER-enriched subtype and molecular apo-
crine tumors. However, no signiﬁcant difference was seen
between HIPK1-negative and nuclear HIPK1-positive
tumors. Tumors with HIPK1 expression in both the cyto-
plasm and nucleus showed frequent small size, node-
negativity and moderately differentiated features. The
mechanisms or reasons why cytoplasmic HIPK1-expressing
tumors showed different clinicopathologic features have not
been investigated, but sumoylation and other post-
translational modiﬁcation might be involved.
In terms of function, the subcellular localization of HIPK
represents an important mechanism in deﬁning its functional
speciﬁcity. HIPK2 can promote apoptosis by down-
regulation of the transcriptional co-repressor CtBP inside the
nucleus (19), while cytoplasmic HIPK1 appears to transduce
signals by death receptors through interaction with TNF re-
ceptor type 1 associated death domain protein and
Fas-associated death domain protein (20,21). HIPK1 has
been reported to be oncogenic and might enhance cell
growth and migration (9,10). However, HIPK1 is desumoy-
lated in response to TNF-a, and desumoylated HIPK1 is
exported to cytoplasm where it binds to the AIP1-ASK1 sig-
naling complex leading to the activation of ASK1-JNK sig-
naling and endothelial cell apoptosis (11). Based on the
previous in vitro models, therefore, cytoplasmic HIPK1 ex-
pression might be associated with enhancing apoptosis and
less aggressive biologic behavior by activation of
ASK1-JNK signaling in breast cancer. However, contradict-
ory ﬁndings were noted by our clinical analyses and cyto-
plasmic HIPK1 expression was associated with aggressive
clinicopathologic features such as high grade, negative
hormone receptors status, HER2-overexpression and high
proliferation. Further study should be necessary.
No signiﬁcant difference in survival was seen by HIPK1
expression. Since HIPK1 expression pattern varied, the
number of tumors in each group was too small to investigate
the statistical signiﬁcance. However, survival showed differ-
ent trends by HIPK1 expression patterns in subgroup ana-
lyses. Molecular apocrine tumors constitute 8–12% of breast
cancers (17,22), and are ER negative but AR positive. Even
though the number of cases was small, a cytoplasmic HIPK1
pattern was signiﬁcantly associated with molecular apocrine
type and none of the ﬁve cases of cytoplasmic
HIPK1-expressing molecular apocrine type breast cancers
showed recurrence or death for up to 10.8 years (71.3–130.6
months; mean: 102 months; median: 101 months) after
surgery (Fig. 3). A large number of cases should be investi-
gated for the conﬁrmation of prognostic implications of
HIPK1 expression patterns in molecular apocrine tumors.
Cytoplasmic HIPK1-postive tumors showed a relatively
better survival trend in the node-positive subgroup,
HER2-postive and ER-negative subgroups (data not shown),
which suggests that the cytoplasmic HIPK1 might play a
protective role in a certain subgroup of breast cancers but
details of molecular mechanism should be explored and in-
dependent validation using a large data set should be
necessary.
Although there are some limitations including the neces-
sity of independent veriﬁcation of immunoreactions using
commercially available antibody for the detection of novel
molecule HIPK1, this study showed that 15% of invasive
breast cancers express HIPK1 with various patterns and cyto-
plasmic expression is associated with distinctive histopatho-
logic characteristics. Sumoylation seems to be associated
Figure 3. Disease-free (A) and overall (B) survival of 59 molecular apocrine tumors according to HIPK1 status. The solid line (a) represents negative HIPK1;
dotted line (b), cytoplasmic HIPK1; dashed line (c), nuclear HIPK1 and dash-dotted line (d), both cytoplasmic and nuclear HIPK1 expression.




















with subcellular localization and different functions of
HIPK1; further experimental and clinical investigations
would be necessary.
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